For other categories (category VI), patients were considered positive if they had a minimum of one symptom from two of the autonomic, neuroendocrine, and immune manifestations
It works by mimicking a hormone that stimulates insulin production after meals and reduces appetite
It can creep up due to skipped meals, dietary changes, or simply a hectic lifestyle
Liu BD, et al
GLP-1 and GIP: The Incretin Synergy Tirzepatide is the first medication to act as a dual agonist of: Glucagon-like peptide-1 (GLP-1) receptor Glucose-dependent insulinotropic polypeptide (GIP) receptor These two hormones are part of the incretin system, a group of gut-derived peptides released in response to food intake
Furthermore, a highly accurate clinical score was developed with a combination of ascites, history of OHE, serum albumin levels, quality-of-life assessment, and the ANT [141]